RU2703297C2 - Композиции и способы для лечения бессонницы - Google Patents

Композиции и способы для лечения бессонницы Download PDF

Info

Publication number
RU2703297C2
RU2703297C2 RU2017112308A RU2017112308A RU2703297C2 RU 2703297 C2 RU2703297 C2 RU 2703297C2 RU 2017112308 A RU2017112308 A RU 2017112308A RU 2017112308 A RU2017112308 A RU 2017112308A RU 2703297 C2 RU2703297 C2 RU 2703297C2
Authority
RU
Russia
Prior art keywords
compound
dosage form
average
daily dose
dose
Prior art date
Application number
RU2017112308A
Other languages
English (en)
Russian (ru)
Other versions
RU2017112308A3 (OSRAM
RU2017112308A (ru
Inventor
Маргарет МОЛИН
Джина ПАСТИНО
Юрие АКИМОТО
Ясухиро ДЗАИМА
Нобуя СУДЗУКИ
Нобуо ЙОСИДА
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2017112308A publication Critical patent/RU2017112308A/ru
Publication of RU2017112308A3 publication Critical patent/RU2017112308A3/ru
Application granted granted Critical
Publication of RU2703297C2 publication Critical patent/RU2703297C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
RU2017112308A 2014-10-23 2015-10-21 Композиции и способы для лечения бессонницы RU2703297C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
US62/067,443 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (3)

Publication Number Publication Date
RU2017112308A RU2017112308A (ru) 2018-11-26
RU2017112308A3 RU2017112308A3 (OSRAM) 2019-05-08
RU2703297C2 true RU2703297C2 (ru) 2019-10-16

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112308A RU2703297C2 (ru) 2014-10-23 2015-10-21 Композиции и способы для лечения бессонницы

Country Status (14)

Country Link
US (3) US10188652B2 (OSRAM)
EP (1) EP3209298B1 (OSRAM)
JP (1) JP6659681B2 (OSRAM)
KR (1) KR102444608B1 (OSRAM)
CN (1) CN107810006B (OSRAM)
AU (1) AU2015336463B2 (OSRAM)
BR (1) BR112017007063A2 (OSRAM)
CA (1) CA2964504C (OSRAM)
ES (1) ES2843952T3 (OSRAM)
IL (1) IL251759B (OSRAM)
MX (1) MX376164B (OSRAM)
RU (1) RU2703297C2 (OSRAM)
SG (2) SG11201703064WA (OSRAM)
WO (1) WO2016063995A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809722C1 (ru) * 2020-04-17 2023-12-15 Шанхай Хайянь Фармасьютикал Текнолоджи Ко., Лтд. Твердый фармацевтический препарат, способ его получения и применение

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
CN109640998A (zh) * 2016-05-12 2019-04-16 卫材研究发展管理有限公司 治疗昼夜节律性睡眠障碍的方法
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
JP7179049B2 (ja) 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
KR20220027981A (ko) * 2019-06-26 2022-03-08 에자이 알앤드디 매니지먼트 가부시키가이샤 수면 문제를 치료하기 위한 렘보렉산트
BR112022004587A2 (pt) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
JP2023508011A (ja) * 2019-12-20 2023-02-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するためのレンボレキサントの使用
JPWO2021145373A1 (OSRAM) * 2020-01-16 2021-07-22
BR112022020924A2 (pt) 2020-04-19 2023-02-14 Idorsia Pharmaceuticals Ltd Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CA3266968A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound
RU2458924C2 (ru) * 2006-12-01 2012-08-20 Мерк Шарп Энд Домэ Корп. Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
CA2220036A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
US7691893B2 (en) 2006-09-11 2010-04-06 Glaxo Group Limited Chemical compounds
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
MX2010002419A (es) 2007-09-21 2010-03-30 Sanofi Aventis (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
WO2011098955A1 (en) * 2010-02-15 2011-08-18 Koninklijke Philips Electronics N.V. Mitigation of control channel interference
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
WO2016063995A1 (en) 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2458924C2 (ru) * 2006-12-01 2012-08-20 Мерк Шарп Энд Домэ Корп. Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EQUIHUA AS et al. "Orexin receptor antagonists as therapeutic agents for insomnia". Front Pharmacol. 2013 Dec 25; 4:163. doi: 10.3389/fphar.2013.00163. *
YEOH JW et al. " Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls". Front Neurosci. 2014 Feb 25; 8:36. doi: 10.3389/fnins.2014.00036. *
СИЛЬКИС И.Г. "Возможные механизмы влияния орексина на функционирование гиппокампа и пространственное обучение (аналитический обзор)". Журнал высшей нервной деятельности им. И.П. Павлова, 2012, т.62, no.4, с.389-400. *
СИЛЬКИС И.Г. "Возможные механизмы влияния орексина на функционирование гиппокампа и пространственное обучение (аналитический обзор)". Журнал высшей нервной деятельности им. И.П. Павлова, 2012, т.62, no.4, с.389-400. YEOH JW et al. " Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls". Front Neurosci. 2014 Feb 25; 8:36. doi: 10.3389/fnins.2014.00036. EQUIHUA AS et al. "Orexin receptor antagonists as therapeutic agents for insomnia". Front Pharmacol. 2013 Dec 25; 4:163. doi: 10.3389/fphar.2013.00163. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809722C1 (ru) * 2020-04-17 2023-12-15 Шанхай Хайянь Фармасьютикал Текнолоджи Ко., Лтд. Твердый фармацевтический препарат, способ его получения и применение

Also Published As

Publication number Publication date
CN107810006A (zh) 2018-03-16
WO2016063995A1 (en) 2016-04-28
JP2017531683A (ja) 2017-10-26
EP3209298A4 (en) 2018-06-20
IL251759B (en) 2021-01-31
US20170252342A1 (en) 2017-09-07
AU2015336463A1 (en) 2017-05-04
KR102444608B1 (ko) 2022-09-20
ES2843952T3 (es) 2021-07-21
US20200268754A1 (en) 2020-08-27
CN107810006B (zh) 2021-03-30
EP3209298A1 (en) 2017-08-30
US10702529B2 (en) 2020-07-07
IL251759A0 (en) 2017-06-29
MX376164B (es) 2025-03-07
US11026944B2 (en) 2021-06-08
CA2964504C (en) 2022-08-23
CA2964504A1 (en) 2016-04-28
SG11201703064WA (en) 2017-05-30
US10188652B2 (en) 2019-01-29
SG10202007759RA (en) 2020-09-29
JP6659681B2 (ja) 2020-03-04
MX2017004950A (es) 2018-01-16
US20190201399A1 (en) 2019-07-04
BR112017007063A2 (pt) 2018-02-14
EP3209298B1 (en) 2020-12-02
KR20170068478A (ko) 2017-06-19
AU2015336463B2 (en) 2020-06-18
RU2017112308A3 (OSRAM) 2019-05-08
RU2017112308A (ru) 2018-11-26

Similar Documents

Publication Publication Date Title
RU2703297C2 (ru) Композиции и способы для лечения бессонницы
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
EP2678320B1 (en) Flumazenil complexes, compositions comprising same and uses thereof
US20120276196A1 (en) Pharmaceutical Compositions of a Neuroactive Steroid and Methods of Use Thereof
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
TW202116314A (zh) T型鈣離子通道調節劑之調配物及其使用方法
EA023758B1 (ru) Применение метадоксина для лечения синдрома дефицита внимания/гиперактивности (adhd/add)
AU2020376950A1 (en) Methods of treatment using an mTORC1 modulator
CN119156202A (zh) 包含阿替卡普兰的组合物
WO2008144665A1 (en) Use of pimavanserin in the treatment of parkinson and symptoms thereof
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
TW200916091A (en) Neramexane for the treatment of nystagmus
CN115003305A (zh) 使用莱博雷生治疗失眠
CA3144067A1 (en) Lemborexant for treating sleep issues
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol